1. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. (November 2020) Authors: Buckley, Christopher D; Simón-Campos, Jesus A; Zhdan, Vyacheslav; Becker, Brandon; Davy, Katherine; Fisheleva, Elena; Gupta, Anubha; Hawkes, Carol; Inman, David; Layton, Mark; Mitchell, Nina; Patel, Jatin; Saurigny, Didier; Williamson, Russell; Tak, Paul P Journal: Lancet Issue: Volume 2:Number 11(2020) Page Start: e677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0228 GSK3196165 AN INVESTIGATIONAL ANTI-GM-CSF MONOCLONAL ANTIBODY, IMPROVES PATIENT REPORTED OUTCOMES IN A PHASE IIB STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA). (June 2019) Authors: Buckley, Chris; Campos, Jesus Simon; Zhdan, Vyacheslav; Becker, Brandon; Chauhan, Deven; Davy, Katherine; Hawkes, Carol; Inman, David; Layton, Mark; Patel, Jatin; Saurigny, Didier; Mitchell, Nina; Williamson, Russell; Tak, Paul Peter Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Psychometric Evaluation of the PROMIS® Pediatric Psychological and Physical Stress Experiences Measures. (27th February 2018) Authors: Bevans, Katherine B; Gardner, William; Pajer, Kathleen A; Becker, Brandon; Carle, Adam; Tucker, Carole A; Forrest, Christopher B Journal: Journal of pediatric psychology Issue: Volume 43:Number 6(2018) Page Start: 678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗